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Summary
VHL tumor suppressor loss results in hypoxia inducible factor-alpha (HIF-α) stabilization, and occurs
in 70% of sporadic clear cell renal carcinomas (ccRCCs). To determine whether opposing influences
of HIF-1α and HIF-2α on c-Myc activity regulate human ccRCC progression, we analyzed VHL
genotype and HIF-α expression in 160 primary tumors, which segregated into three groups with
distinct molecular characteristics. Interestingly, ccRCCs with intact VHL, as well as pVHL-deficient,
HIF-1α/HIF-2α expressing ccRCCs, exhibited enhanced Akt/mTOR and ERK/MAPK signaling. In
contrast, pVHL-deficient ccRCCs expressing only HIF-2α displayed elevated c-Myc activity,
resulting in enhanced proliferation and resistance to replication stress. These reproducible
distinctions in ccRCC behavior delineate HIF-α effects on c-Myc in vivo and suggest molecular
criteria for selecting targeted therapies.
Significance—Constitutive HIF activity is clearly associated with ccRCC tumorigenesis; however,
the influence of individual HIF-α subunits on cell growth mechanisms in vivo is unknown. Few
dominant oncogenic pathways have been identified within ccRCC, making it difficult to select
optimal targeted therapies for patients, or to predict disease outcome, except by grade and stage. Cell
culture experiments indicate that HIF-1α inhibits the c-Myc oncoprotein, whereas HIF-2α potentiates
c-Myc transcriptional activity and cellular proliferation. The findings reported here indicate that
HIF-1α and HIF-2α promote distinct oncogene activation in human ccRCCs, and reveal a critical
role for HIF-2α and c-Myc in promoting genomic integrity. These results suggest that evaluating
pVHL status and HIF-α expression may aid targeted therapy selection for human ccRCCs.
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Mutation or silencing of the von Hippel-Lindau (VHL) tumor suppressor gene occurs in a
majority of inherited and sporadic clear cell renal cancers (ccRCC) (Banks et al., 2006; Kim
and Kaelin, 2004; Kondo et al., 2002b; Lonser et al., 2003). VHL encodes pVHL, a critical
regulator of the hypoxia inducible factor (HIF) transcriptional activators (Kim and Kaelin,
2004). HIFs are heterodimeric bHLH-PAS proteins, consisting of an α subunit (HIF-1α or
HIF-2α) and a β-subunit (HIF-1β or ARNT [for aryl hydrocarbon receptor nuclear
translocator]). HIFs mediate cellular adaptation to low O2 by activating the transcription of
target genes involved in metabolism, angiogenesis, and extracellular matrix (ECM) remodeling
(Gordan and Simon, 2007; Pugh and Ratcliffe, 2003). pVHL is part of the recognition
component of a ubiquitin ligase complex that targets HIF-α subunits for normoxic degradation,
a process that is inhibited under hypoxic conditions (typically <5% O2) by several mechanisms.
Although pVHL has additional molecular functions affecting fibronectin assembly (Kim and
Kaelin, 2004), microtubule stability (Hergovich et al., 2003), and atypical Protein Kinase C
activity (Lee et al., 2005), results from ccRCC xenograft experiments indicate that HIF-α
regulation is critical for VHL tumor suppressor function.
HIF-1α and HIF-2α have overlapping effects on aspects of angiogenesis and ECM remodeling;
however, they also exhibit distinct effects on cell metabolism and proliferation (Gordan et al.,
2007b). For example, HIF-1α is uniquely able to stimulate glycolytic enzyme expression (Hu
et al., 2003; Wang et al., 2005) while blocking anabolic biosynthesis by limiting mitochondrial
pyruvate consumption (Kim et al., 2006; Lum et al., 2007; Papandreou et al., 2006). HIF-1α
also opposes cell cycle progression in vitro by post-translationally inhibiting the c-Myc
oncoprotein (Koshiji et al., 2004). In direct contrast, HIF-2α does not regulate glycolytic gene
expression (Hu et al., 2003), but uniquely stimulates expression of the stem cell factor Oct-4
(Covello et al., 2006), and promotes cell cycle progression by enhancing c-Myc-mediated
activation of cyclin D2 and E2F1, and repression of p21 and p27 (Gordan et al., 2007a).
Intriguingly, independent reports demonstrated that the HIF-2α subunit is primarily responsible
for the growth of pVHL-deficient human ccRCC xenografts (Kondo et al., 2003; Kondo et al.,
2002a; Maranchie et al., 2002). Moreover, in VHL disease, the cancer susceptibility syndrome
associated with germline VHL mutation, HIF-1α expression gradually decreases whereas
HIF-2α expression increases as ccRCCs develop (Mandriota et al., 2002; Raval et al., 2005).
The differential effects of HIF-1α and HIF-2α on c-Myc provide an appealing mechanistic
explanation for the activity of HIF-2α in VHL disease-associated ccRCC (Mandriota et al.,
2002; Raval et al., 2005). However, no studies have directly assessed the differential effects
of HIF-1α and HIF-2α on c-Myc or other oncogenic pathways in human ccRCC.
In addition to driving cellular proliferation, oncogenes can also contribute to genomic
instability by disrupting cell cycle controls and cellular metabolism (Halazonetis et al.,
2008). Cell cycle checkpoint inactivation allows DNA replication in aneuploid cells, and may
favor oncogenic genomic amplifications by repetitively triggering replication origins during a
single S-phase (Hook et al., 2007). Furthermore, many oncogenes alter cellular metabolism,
leading to the production of reactive oxygen species that directly modify DNA (Lee et al.,
1999). Both processes result in disrupted chromosomal structures and replication fork stalling
or collapse, triggering a cell-intrinsic DNA damage response (Bartkova et al., 2005; Gorgoulis
et al., 2005). In low stage tumors, this damage causes a G0-like phenotype following
incomplete DNA replication (Bartkova et al., 2006; Di Micco et al., 2006), while its impact on
more advanced tumors is less clear. High levels of c-Myc overexpression can result in
accumulation of significant DNA damage (Ray et al., 2006; Vafa et al., 2002). In contrast,
intermediate c-Myc expression levels may actually promote genomic stability, consistent with
the observation that DNA damage is reduced when c-Myc is inhibited by HIF-1α (Huang et
al., 2007; Koshiji et al., 2005). Therefore, we also examined the possibility that activation of
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c-Myc by HIF-2α might enhance genomic stability in low stage ccRCCs, thus enhancing tumor
cell proliferation by limiting DNA damage checkpoint activation.
In this report, we describe the characterization of more than 160 sporadic human ccRCC tumor
samples based on VHL genotype and HIF-α expression patterns. Our initial investigations
identified three distinct ccRCC groups: (1) tumors with wild type VHL alleles and undetectable
HIF-α protein expression (designated “VHL WT”), (2) VHL-deficient tumors expressing
detectable HIF-1α and HIF-2α proteins (designated “H1H2”), and (3) VHL-deficient tumors
expressing HIF-2α exclusively (designated “H2”). VHL WT, H1H2, and H2 tumors were
extensively characterized for differences in cell proliferation, patterns of oncogene activation,
and genomic integrity. These analyses were extended to include two independent renal cancer
sample sets and HIF-1α or HIF-2α deficient tumor cell lines. We wished to determine if human
ccRCCs can be subclassified into distinct groups based on VHL status and HIF-α expression
patterns, which in turn correspond to the activation of distinct oncogenic signaling and DNA
repair pathways. The overall objective of these studies is to ultimately provide a strategy to
stratify patients for targeted therapies.
Results
Identifying three groups of ccRCC
We determined the HIF-α expression patterns and VHL status of 57 independent sporadic
human ccRCCs obtained from the Collaborative Human Tissue Network (CHTN). HIF
immunostaining patterns separated the tumors into three distinct groups: no HIF-α protein
detected (“VHL WT,” 12%), HIF-1α and HIF-2α detected (“H1H2,” 61%), or HIF-2α detected
exclusively (“H2,” 27%). Classification was based on HIF-α expression solely in tumor cells.
Interestingly, none of the sporadic tumors we evaluated expressed only HIF-1α, strongly
suggesting that HIF-2α is critical for development of pVHL-deficient human ccRCCs. HIF-
α protein staining in H1H2 and H2 specimens was predominantly nuclear and appeared in
>75% of tumor cells, whereas VHL WT tumors exhibited HIF-α staining in <5% of nuclei (Fig.
1A). VHL sequencing, copy number and methylation analysis confirmed that all HIF-α negative
tumors (7/7) had wild type VHL alleles, whereas all but one of the HIF-α positive tumors (49/50)
harbored bi-allelic VHL inactivation by mutation, deletion or methylation (Fig. 1B and
Supplemental Table 1). Most tumors displayed single allele point or frameshift VHL mutations,
accompanied by deletion of the remaining allele. The spectrum and relative frequencies of
VHL mutations were consistent with published analyses of sporadic ccRCC (Banks et al.,
2006;Kondo et al., 2002b). Similar to previous observations (Banks et al., 2006;Kondo et al.,
2002b), we found two tumors with one deleted and one intact VHL allele: of these, one tumor
had no HIF-α staining and was classified VHL WT, whereas the other exhibited faint, but
distinct, HIF-2α staining and was excluded from further analysis.
Multiple controls were performed to substantiate the immunohistochemistry (IHC) and
genotyping. As measured by QRT-PCR, VHL mRNA levels were reduced to <50% and <20%
of normal renal epithelium in VHL-mutant tumors and VHL-methylated tumors, respectively
(data not shown). HIF-α protein was measured by western blot assays, and protein levels in
the three subgroups were consistent with IHC results. Immunoblots showed low levels of
HIF-1α expression in H2 tumors (less than 10% the level in H1H2 tumors), which likely reflects
HIF-1α protein in endothelial cells (Supplemental Figure 1). By comparing tumor protein
extracts to known quantities of epitope-tagged HIF-α protein, we determined that HIF-1α and
HIF-2α are expressed at essentially equivalent levels in H1H2 tumors (Supplemental Figure 1
and data not shown). There was no clear difference in HIF-1α mRNA levels between H1H2
and H2 tumors, although slightly increased HIF-2α mRNA levels were noted in H2 tumors
(data not shown). The apparent discrepancy between HIF-1α mRNA and protein expression
in H2 tumors can be explained by multiple mechanisms, including mutant pVHL proteins that
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selectively promote HIF-1α degradation (Rathmell et al., 2004) and direct effects of HIF-2α
on HIF-1α mRNA translation (Raval et al., 2005). Finally, available clinical information was
segregated by group and no significant differences were observed between VHL WT, H1H2,
or H2 tumors in either grade or stage of disease at surgery, although VHL WT tumors showed
a trend toward more frequent metastasis (Fig. 1C).
HIF-α expression modulates oncogene activation
Based on results from cell culture models (Gordan et al., 2007a), we hypothesized that H2
tumors would display evidence of increased c-Myc activity. Indeed, expression of c-Myc-
activated targets Cyclin D2 and E2F1 was 2–3 fold higher in H2 tumors than H1H2 or VHL
WT tumors when measured by QRT-PCR (Fig. 2A). Similarly, c-Myc-repressed targets p21
and p27 were decreased in H2 tumors (Fig. 2B). To rule out alterations in overall c-Myc
expression levels as an explanation for these results, c-Myc mRNA and protein abundance
were measured, and no consistent difference was found between groups (Fig. 2A and data not
shown), nor were significant c-Myc amplifications detected with Q-PCR (Supplemental Table
1). Ki-67 staining was performed to quantify cell proliferation (Fig. 2C), and a 55% increase
in Ki-67+ nuclei was observed in H2 relative to H1H2 tumors (Fig 2D). The clearest difference
was between low stage tumors, which displayed approximately 60% more Ki-67+ nuclei in H2
tumors than in VHL WT or H1H2 tumors, although the analysis of high stage tumors was
limited by the smaller number in this sample set (Fig. 2D). Overall, these data support our
hypothesis that HIF-2α activation of c-Myc occurs in human tumor specimens, and correlates
with increased tumor cell proliferation. Although HIF-2α is expressed in H1H2 tumors, our
previous data show that HIF-1α-mediated c-Myc inhibition directly opposes HIF-2α-mediated
c-Myc activation (Gordan et al., 2007a). Consistent with these data, H1H2 tumors displayed
levels of c-Myc target gene expression similar to that in VHL WT tumors.
To extend these analyses in an unbiased manner, mRNA expression profiling was performed
to identify global transcriptional effects of differential HIF-α expression. VHL WT tumors were
included, both as a comparison group and to identify unique markers of ccRCCs lacking HIF-
α expression. Five VHL WT, 8 H1H2 and 8 H2 tumors were analyzed. These tumors were
selected to represent a similar range of early and advanced lesions in each group, and for optimal
RNA quality. Comparisons were performed between VHL WT and VHL-deficient tumors, and
between H1H2 and H2 tumors, identifying a large number of differentially expressed genes
(Supplemental Table 2), a subset of which are discussed further here. These comparisons
revealed that H2 tumors express elevated levels of additional c-Myc responsive transcripts
involved in the G1-S phase cell cycle transition (Coller et al., 2000; O’Connell et al., 2003),
including Skp2, Cdc7, CDT2, and dihydrofolate reductase (DHFR) (Fig. 2E and Supplemental
Table 2). In contrast, VHL WT and H1H2 tumors expressed lower, but relatively similar, levels
of these targets, as discussed above. IHC for Skp2 (Supplemental Fig. 2A,2B) and
immunoblotting for Skp2 and Cdc7 (Supplemental Fig. 2C) confirmed that changes in mRNA
levels were reflected in protein expression. The c-Myc antagonist Mxi was upregulated in
VHL-deficient tumors (Corn et al., 2005; Zhang et al., 2007), consistent with decreased
expression of c-Myc regulated mitochondrial enzyme gene expression relative to VHL WT
tumors (Supplemental Table 2). However, Mxi appeared to have limited impact on other c-
Myc targets, as c-Myc regulated cell cycle genes were induced in H2 tumors, but not VHL WT
tumors, despite increased Mxi expression.
In striking contrast to c-Myc activation in H2 tumors, H1H2 tumors displayed increased
expression of the growth factor signaling molecules Akt2 and RhoC, as well as ribosomal L,
S and P proteins and the rRNA transcriptional regulator upstream binding factor (UBF). Several
of these genes were also expressed at higher levels in VHL WT tumors relative to H2 samples
(Fig. 3A). Intriguingly, we also noted increased expression of genes encoding cytoskeletal
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proteins in VHL WT and H1H2 tumors. This may be a result of enhanced growth factor
signaling, given the impact of growth factor responsive proteins such as Rho C on cell motility.
These changes in mRNA levels could represent an adaptive mechanism in H1H2 tumors, as
VHL loss is associated with decreased matrix deposition and loss of cell polarity (Kim and
Kaelin, 2004). To assess growth factor signaling more directly, we performed IHC for
phosphorylated extracellular regulated kinase (ERK, also referred to as mitogen-actived
protein kinase 1, or MAPK1) and ribosomal protein S6, a target of the mTOR substrate p70
S6 Kinase (Fig. 3B). These proteins are critical signaling molecules whose phosphorylation is
induced by multiple growth factor signal transduction pathways. Increased phospho-S6 and
phospho-ERK staining was observed in VHL WT and H1H2 compared to H2 tumors (p<.05
for H1H2 vs. H2, Fig. 3C). In H2 tumors, detectable phospho-S6 immunostaining was not
observed in tumor cells, but rather restricted to stromal cells associated with blood vessels (Fig.
3B, red arrows). These findings define a functional distinction between ccRCC subsets:
whereas c-Myc appears to drive proliferation in H2 tumors, VHL WT and H1H2 tumors utilize
growth factor signaling pathways acting on ERK and S6.
As expected, the expression profiling experiments also revealed increased expression of
multiple shared HIF-1α and HIF-2α targets (vascular endothelial growth factor,
andrenomedullin, etc.) in all VHL-deficient tumors. Similarly, H1H2 tumors (but not H2
tumors) expressed elevated levels of HIF-1α specific target genes, such as those encoding
glycolytic enzymes (Hu et al., 2003) (Supplemental Table 2). When two-way clustering was
performed on the microarray data, tumors largely segregated into the same groups defined
prospectively by HIF-α expression (Fig. 3D). Gene ontology analysis (Ficenec et al., 2003)
also identified classes of differentially expressed genes in addition to those discussed here (Fig.
3D). Thus, the key features of each tumor subtype were consistently observed within groups,
with activation of c-Myc targets detected exclusively in H2 tumors, in contrast to upregulated
growth factor signaling components in VHL WT and H1H2 tumors.
HIF-2α limits DNA damage accumulation
DNA damage from replication stress is commonly observed in hyperproliferative tumor cells,
and can trigger a signaling pathway including ATR, ATM, phospho-Chk1, phospho-Chk2 and
phospho-histone H2AX (γH2AX) (Bartkova et al., 2005; Gorgoulis et al., 2005), potentially
resulting in cell cycle checkpoint activation. The ability to repair DNA damage through
homologous recombination (HR) and non-homologous end joining (NHEJ) overcomes these
responses and promotes cellular proliferation. In our expression profiling studies, we observed
enhanced expression of the HR effectors BRCA1, BARD1, and XRCC2, as well as spindle
assembly checkpoint genes BUB1 and CENPE, in H2 tumors compared to VHL WT and H1H2
tumors (Supplemental Table 2). We confirmed these findings with QRT-PCR (Fig. 4A).
Immunofluorescence for γH2AX and Ki-67 revealed that H2 tumors contained 50% fewer
strongly γH2AX+ nuclei than VHL WT or H1H2 tumors, with a clear difference in γH2AX+/
Ki-67+ nuclei (H2 tumors <20% of VHL WT or H1H2) (Fig. 4B,C). Phospho-Chk2 staining
also correlated to γH2AX staining patterns (Fig. 4D). The dramatic decrease in γH2AX+/
Ki-67+ nuclei in H2 tumors strongly suggests that they accumulate less DNA damage during
replication. DNA damage was directly measured by assessing the percentage of the genome
that was aberrant (amplified or deleted) in 10 H1H2 and 11 H2 tumors by array-based
Comparative Genomic Hybridization. Of note, a statistically significant 40% reduction was
noted in H2 tumors (Figure 4E).
As our expression data implicated HR effectors in DNA damage responses in H2 tumors, we
assessed protein abundance and function by immunofluorescence. When tumor sections were
stained for BARD1, expression was detected at homogeneous levels within each section, but
differences were noted in the number of foci between tumors (Fig. 5A). There was a statistically
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significant increase in the number of H2 tumors with moderate to high numbers of BARD1
foci (defined as 15–30 and >30 foci/nucleus respectively) compared to H1H2 tumors. This
difference was also significant when H2 tumors were compared to H1H2 and VHL WT tumors
grouped together (Fig. 5B). Whereas BARD1 staining tended to be homogeneous within tumor
sections, BRCA1 staining (Fig. 5C) was more variable between nuclei for a given tumor.
BRCA1 was present in a higher proportion of all nuclei in H2 tumors, including those that
were γH2AX+ (Fig. 5D), suggesting that HR activity reduces the accumulation of stalled and
collapsed replication forks in H2 tumors.
To test the role of HIF-α subunits in HR effector expression directly, we employed a VHL-
mutant ccRCC cell line (RCC4) that expresses both HIF-1α and HIF-2α. Vector-transduced
control cells were compared to HIF-1α knockdown (H1KD) cells (“H1KD.1” and “H1KD.2”)
or HIF-2α knockdown (H2KD) cells (“H2KD.1” and “H2KD.2”) (Fig. 6A and Supplemental
Figure 3A). Expression of a common HIF-1α and HIF-2α target gene (VEGF), a HIF-1α
specific target gene (PGK), and a HIF-2α specific target gene (Oct-4) (Covello et al., 2006;Hu
et al., 2003) was assessed to confirm functional HIF-α knockdown in these cells (Supplemental
Fig. 3B). H1KD cells retain HIF-2α activity, and displayed enhanced c-Myc activity with
elevated cyclin D2 and E2F1 expression, and decreased p21 and p27 expression. In contrast,
decreased c-Myc activity was observed in H2KD cells, which retain HIF-1α expression (Fig.
6B). Similarly, HIF-1α knockdown promoted S-phase entry, enhancing proliferation, whereas
HIF-2α knockdown caused accumulation in G1 and limited proliferation (Supplemental Fig.
3C, 3D). Expression of other c-Myc targets, including Skp2, CDC7, BARD1, and BRCA1 was
found to be stimulated by HIF-1α knockdown (Fig. 6C) and inhibited by HIF-2α knockdown,
consistent with our observations using primary ccRCCs. Although these mRNA changes are
modest, they are likely to have additive effects. In the case of BRCA1, they also correspond
to more dramatic changes in protein expression (Fig. 6D). HIF-1α and HIF-2α effects on
BRCA1 and BARD1 mRNA expression were c-Myc-dependent, based on siRNA knockdown
of c-Myc expression (Fig. 6E), consistent with previous studies showing that c-Myc stimulates
BRCA1 expression (Bindra et al., 2005;Koshiji et al., 2004). Thus, manipulating the
stoichiometry of HIF-1α and HIF-2α in RCC4 cells can modulate c-Myc activity, resulting in
altered expression of HR mediators.
H1KD and H2KD cells were also evaluated for their response to hydroxyurea (HU)-induced
replication stress. HU blocks nucleotide synthesis and inhibits DNA replication, resulting in
replication fork stalling and ATR-mediated Chk1 phosphorylation. Failure to resolve stalled
replication forks leads to their collapse and activation of ATM, Chk2 and p53, which can
promote cell cycle arrest or senescence (Branzei and Foiani, 2007; Wang, 2007). Resolution
of stalled forks requires HR, which is known to occur in BRCA1 nuclear foci (Wang, 2007).
HU-treated H1KD (HIF-2α expressing) cells displayed >50 BRCA1 foci per nucleus, whereas
<10 foci were detected in H2KD (HIF-1α expressing) cells. We also noted that H1KD cells
exhibited less dramatic γH2AX staining when compared to control or H2KD cells (Fig. 6F).
In each case, BRCA1 and γH2AX foci displayed overlapping nuclear distributions (Fig. 6F).
These data are consistent with the large number of BRCA1 foci observed in H2 tumors, and
suggest a specific role for HIF-2α in DNA damage responses in ccRCCs.
Functional consequences of differential DNA damage signaling in HIF-α knockdown cells
were examined. HU treatment of cells synchronized in S-phase induced rapid Chk1
phosphorylation in all lines, suggesting equivalent activation of the intra-S-phase checkpoint
(Fig. 7A). In contrast, Chk2 phosphorylation and γH2AX were decreased in H1KD cells
compared to control cells, mirroring the differences observed between H2 and H1H2 tumor
specimens (Fig. 7A, left panel), while the opposite result was observed in H2KD cells (Fig.
7A, right panel). Interestingly, H1KD cells returned more rapidly to cell cycle progression after
HU treatment, whereas H2KD cells recovered more slowly (Fig. 7B). These data support the
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notion that HIF-2α, in contrast to HIF-1α, promotes more efficient HR-mediated repair and
resolution of replication stress, reducing the accumulation of DNA damage and activation of
checkpoint responses.
We used an independent experimental approach to evaluate the effect of HIF-α expression on
cell cycle progression under conditions of replication stress. Cells were incubated in a low
concentration of aphidicolin (1 μg/ml) for 20 hours, a concentration at which aphidicolin
reduces DNA polymerase progression through complex genomic structures and can activate
an intra-S-phase checkpoint characterized by cells with hyper-diploid DNA content (>2N). In
RCC4 cells, HIF-1α knockdown promoted successful completion of S-phase, indicated by a
significant decrease in the proportion of >2N cells compared to control lines (Fig. 7C), and
consistent with the hypothesis that these cells respond more effectively to DNA replication
stress. In contrast, H2KD cells showed a trend toward failure to complete S-phase (p=.06).
Interestingly, cells completing G1 in the presence of low-dose aphidicolin treatment are
capable of firing early origins of replication and incorporating BRDU, although DNA synthesis
at newly fired origins is severely diminished (Dimitrova and Gilbert, 2000); consequently,
these cells appear as BRDU-positive with 2N DNA content (2N/BRDU+). H1KD and H2KD
cells were treated with aphidicolin as described above, and then pulsed with BRDU for 20
minutes to label newly fired origins in cells that had successfully completed G1. H1KD cells
showed a significantly higher rate of replication initiation compared to controls, reflected as
2N/BRDU+ cells, whereas H2KD cells showed significantly lower rates (Fig. 7C). In summary,
HIF-2α expression (in the absence of HIF-1α was correlated with increased BRCA1 expression
and efficient S-phase completion, thereby permitting cell cycle progression in the face of
replication stress while limiting phospho-Chk2 and γH2AX accumulation. Conversely,
HIF-1α expression was associated with elevated markers of DNA damage and a limited ability
to proliferate when challenged with replication stress, in keeping with the model presented in
Figure 7D. Importantly, results from these functional in vitro studies using replication stress
mimetics are consistent with our observations of DNA stress markers in ccRCC tumors.
Validation of expression and signaling changes in additional tumor samples
Having identified HIF-α-intrinsic effects on cell cycle and DNA repair pathways in human
tumor specimens, we sought to confirm them in two independent sets of patient samples.
Microarray analysis was performed on a second group of 12 ccRCCs, collected at the
University of North Carolina. All tumors were scored as VHL-deficient because they showed
strong HIF-α staining in >75% of cells, significant upregulation of multiple HIF targets, and
decreased VHL expression compared to controls. Samples were separated into H1H2 and H2
subgroups (n=7 and 5, respectively), and differentially expressed genes analyzed. As described
above, tumors clustered by HIF-α expression (Supplemental Fig. 4A), exhibiting gene
expression consistent with increased glycolytic metabolism and growth factor signaling in
H1H2 tumors, and enhanced cell cycle progression and HR gene expression in H2 tumors.
Comparing these results to our primary analysis, we observed a 30–40% concordance between
the data sets (p < 1×10−12), commensurate with published reports comparing arrays performed
under similar conditions (Subramanian et al., 2005). Ki-67 staining (Supplemental Fig. 4B)
was also consistent with data from our initial tumor set. Genes exhibiting increased expression
in all H2 tumors are listed in Supplemental Figure 3C, and include Cyclin D2, E2F1, Skp2,
DHFR, BARD1, and BRCA1.
To confirm the biological phenotypes described above, and analyze a data set with information
regarding clinical outcome, IHC was performed on a tissue microarray (TMA) containing
triplicate samples from 93 randomly selected ccRCCs from the University of Pennsylvania.
TMA slides were immunostained for HIF-1α and HIF-2α proteins (Fig. 8A) and a similar
distribution of the three groups was observed (Fig. 8B). Tumors were categorized as VHL WT
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if neither HIF-1α nor HIF-2α staining was observed. The tumors in this data set tended to be
of lower stage than the initial group, but a similar proportion was metastatic at presentation.
Metastatic relapse was observed in H1H2 and H2 tumors over a median six years of follow
up, with comparable overall rates between groups (Fig. 8B). Notably, H2 tumors were
significantly larger in volume when compared to VHL WT or H1H2 (Fig. 8B, p <.008 and .04,
respectively). Ki-67, phospho-S6 and γH2AX staining was performed, and H2 tumors
displayed 60% more Ki-67+ cells relative to H1H2 and VHL WT tumors (Fig. 8C), whereas
phospho-S6 (Fig. 8D,E) and γH2AX (Fig. 8F,G) staining was significantly higher in both
VHL WT and H1H2 compared to H2 tumors. These data extended our analysis of HIF-α effects
to advanced tumors, which had not previously been possible in the smaller initial tumor
collection. These two data sets (105 additional samples) confirm and extend the phenotypic
characterization of the initial ccRCC subgroups (Fig. 1), as well as the increased expression
of specific gene targets in H2 tumors (Supplemental Table 2) associated with increased cell
cycle progression and HR.
Discussion
Human ccRCCs are typically subdivided into two clearly distinct groups based on VHL status.
Approximately 70% of sporadic ccRCCs have lost pVHL expression through VHL deletion
and/or silencing (Banks et al., 2006; Kim and Kaelin, 2004), but additional criteria by which
pVHL-deficient tumors can be classified have not been described. Here, we demonstrate that
VHL-deficient ccRCCs can be distinguished on the basis of differential HIF-α expression, and
consequent HIF-dependent effects on c-Myc activity. Specifically, we found that H2 tumors
displayed enhanced c-Myc activity, higher rates of proliferation, increased volume and lower
levels of γH2AX accumulation than H1H2 or VHL WT tumors. In contrast, H1H2 and VHL
WT tumors displayed increased activation of Akt/mTOR and ERK/MAPK1 growth factor
signaling pathways and enhanced γH2AX accumulation. Although VHL WT and H1H2 tumors
generally share these traits, prior work (Turner et al., 2002) and our expression profiling data
strongly suggest that H1H2 tumors are more angiogenic than VHL WT tumors. This study
presents evidence of differential HIF/c-Myc effects in patient-derived tumor samples, and
describes a previously unappreciated interplay between HIF-2α, c-Myc and genome stability.
Together, these data provide a mechanistic basis to subdivide ccRCC for molecularly targeted
therapy.
The in vitro and in vivo findings presented here extend HIF-2α/c-Myc cell cycle effects to
include promotion of efficient transit through S-phase by stimulating expression of HR
mediators, as well as genes encoding proteins that limit replication stress by enhancing
nucleotide pools (DHFR) (Milbrandt et al., 1981) or blocking re-replication (Skp2 and Cdt2)
(Nishitani et al., 2006). As HIF-1α and HIF-2α have opposite effects on c-Myc, our findings
are consistent with previous observations that HIF-1α inhibits mismatch repair by blocking c-
Myc activity (Koshiji et al., 2005). It should be noted, however, that hypoxia directly promotes
genomic instability in a HIF-1α independent fashion (Bristow and Hill, 2008). Thus, tumors
expressing only HIF-2α may be able to compensate for hypoxia-induced genomic instability.
Intriguingly, our findings suggest that Mxi upregulation by HIF-1α and HIF-2α (Zhang et al.,
2007) exerts a specific effect on mitochondrial metabolism, without impacting several other
c-Myc driven processes. These results delineate the in vivo impact of HIF/c-Myc effects in
ccRCC, and highlight contrasting properties of HIF-1α and HIF-2α on c-Myc-regulated DNA
damage repair.
The decreased levels of γH2AX and increased numbers of Ki-67+ nuclei observed in H2 tumors
reveal a correlation between enhanced proliferation and decreased levels of DNA damage.
Given the concomitant upregulation of HR effectors BRCA1 and BARD1, these findings
implicate enhanced resolution of replication stress as a mechanism by which tumor cells escape
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the cell cycle block imposed by DNA damage-activated checkpoints. The fact that HIF-2α-
expressing RCC4 cells, which display enhanced BRCA1 and BARD1 expression, recover more
rapidly from HU and aphidicolin further supports the hypothesis that enhanced HR contributes
to tumor cell proliferation in the context of replication stress. Similarly, a key role for HR in
normal cell cycle progression has been suggested by targeted mutation of murine BRCA1 and
BARD1, as disruption of either gene dramatically limits proliferation in embryonic cells
(McCarthy et al., 2003; Xu et al., 1999). Differing levels of replication stress could underlie
the variable activation of DNA damage response machinery observed in different tumor types.
For example, whereas tumors of the lung, bladder, and skin appear dependent on stepwise
dismantling of DNA damage responses for progression (Bartkova et al., 2005; Gorgoulis et
al., 2005), recent studies suggest that stomach, colorectal and breast adenocarcinoma, as well
as testicular germ cell tumors, have minimal DNA damage response activation at all stages
(Bartkova et al., 2007; Nuciforo et al., 2007). More efficient progression through S-phase has
not been previously described as a pathway for enhanced tumor cell proliferation, and is likely
to be of particular importance in early stage tumor cells with intact DNA damage checkpoints.
The combination of VHL genotype and HIF-α expression allows the stratification of ccRCCs
into biologically distinct groups, and suggests a framework for sub-classifying tumors for
targeted therapies. Although several targeted drugs with distinct mechanisms of action are
available to treat metastatic ccRCC, there are currently no parameters to select the optimal drug
for each patient. Sunitinib and sorafenib each appear to inhibit tumor angiogenesis and tumor
cell viability through their effects on VEGF signaling in endothelial cells and, potentially,
tumor cells. These agents differ with respect to the potency of their interactions with VEGF
and PDGF receptors and most notably with respect to the Raf/MAP kinase pathway, an
exclusive target of sorafenib. We suggest that growth factor driven ccRCCs (VHL WT and
H1H2) are more likely to respond to these drugs. Similarly, while treatment with erlotinib
(targeting the epidermal growth factor receptor) and bevacizumab (inhibiting angiogenesis)
conferred no benefit as compared to bevacizumab alone in unselected patients (Motzer and
Bukowski, 2006), this combination might exclusively show increased efficacy against the
H1H2 subset. Furthermore, whereas the anti-angiogenic effects of sorafenib and sunitinib
should impact vascularity in H2 tumors, they are nevertheless likely to progress, as HIF-2α
dependent c-Myc activation could promote growth in relatively well-oxygenated tumor
subdomains. Expression of HIF-2α alone may therefore mark a subset of RCC that is uniquely
resistant to the current targeted therapeutics. While retrospective and prospective studies with
associated clinical trial data are needed to demonstrate a connection between HIF-α expression
and therapeutic response, HIF-α analysis enables us to stratify ccRCC patients and thus




Frozen material for the primary analysis was obtained through the Collaborative Human Tissue
Network. OCT embedded blocks were sectioned until cut planes were >70% tumor. Sections
were collected for DNA, RNA and protein extraction. Material for TMA analysis was obtained
from archival specimens at the University of Pennsylvania. Both protocols were approved by
the IRB at the University of Pennsylvania. Samples were catalogued, clinical information on
cases was obtained through chart review, and patient identifiers were removed before analysis.
Material for microarray validation was collected at the University of North Carolina from
surgeries performed on site. An approval was given by the IRB at UNC.
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VHL Sequence and Methylation Analysis
DNA was extracted from tumor samples using the EX-WAX DNA extraction kit (Chemicon).
Mutation screening was performed on PCR amplified exons by direct sequencing with
BigDyeTerminator Cycle kit on a 3130xl sequencer (Applied Biosystems). Primers and
protocols were used as previously described (Stolle et al., 1998). Methylation studies were
performed using the CpG Wiz Kit (Chemicon, Inc) and/or Not1 digestion (Herman et al.,
1994).
Immunohistochemistry
For frozen specimens, 10 μM sections were fixed with 4% paraformaldehyde, permeabilized
with PBS/.5% Triton X-100 and stained following standard protocols, detailed further in the
Supplemental text. For HIF-α staining, slides were scored as positive if more than 40% of
nuclei stained positive. Cytoplasmic staining was not considered. For Ki-67, Skp2, γH2AX,
phospho-Chk2, and BRCA1, 3–4 high power images were counted for percentage positive,
and then averaged to give a mean rate per tumor, except for Ki-67 on TMA cores, where the
entire core was counted in each case. Only cells with clear tumor cell morphology were scored.
For phospho-ERK, phospho-S6, and BARD1, samples were scored as negative/weak,
intermediate or strong. For these and HIF-α staining, analysis was reviewed by multiple
investigators, including J.D.G., P.L. and K.N.P.
TMA Design and Production
94 ccRCC samples were selected from tissue archives at University of Pennsylvania,
representing 93 primary tumors and one metastasis. H&E stained sections were evaluated to
confirm the initial diagnosis, and three 0.6 mm tissue cores were selected from different areas
of each tumor. Matched normal renal epithelium was included for 2/3 of cases, and renal
angiomyolipomas and spleen cores were also included as staining controls. Cores were
assembled and cut into sections as previously described (Kononen et al., 1998).
Microarrays
Primary expression microarray analysis was performed at the University of Pennsylvania
Microarray Core using the Affymetrix U133 Plus 2.0 array, with analysis using Gene Pattern
(Broad Institute) (Reich et al., 2006). Array-based Comparative Genomic Hybridization
(aCGH) was also performed at the University of Pennsylvania Microarray Core using the
Illumina 550K-2 v3.1 array and analyzed with Partek Genomics Suite, while the validation set
of expression arrays was hybridized at the University of North Carolina Genomics Core using
the Agilent 4×44K array format, with a standard reference RNA used in the second channel
and analyzed with Statistical Analysis of Microarrays (SAM). Analytical methods are
described in the Supplemental Methods.
Statistical Analysis
Significance was typically evaluated by two-tailed student’s T test. When t tests were
performed on data from multiple measurements (i.e., counting 4 images of one slide), values
were averaged by tumor before inclusion in the test. For non-continuous measurements,
Fisher’s Exact Test was used, with 2×2 tables except for phospho-S6 and phospho-ERK
staining where 2×3 and 3×3 Chi-squared tables were used.
Cell Culture, Drug Treatments and Synchronization
RCC4 cells were cultured in DMEM with 10% FCS (Gemini), standard additives, and 1 ug/
ml puromycin. Knockdown clones were generated by retroviral transduction using pBABE
HIF-1α shRNA (Lum et al., 2007), and pRETROSUPER HIF-2α shRNA (Kondo et al.,
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2003) (generous gift of W.G. Kaelin). Hydroxyurea (Sigma) was prepared in water and used
at 1.5 mM. Aphidicolin was prepared in DMSO and used at 1 μg/ml. Cells were synchronized
in G1 by confluency and serum withdrawal for 24 hours, and released by trypsinization and
replating. H1KD, control and H2KD cell lines were released 18, 20 and 22 hours respectively
before HU treatment, ensuring 50–60% of cells in S Phase and the remainder in G1. All other
in vitro methods are described in Supplemental Text.
Accession Numbers
The raw data for expression profiling and SNP based copy number data are available through
the Gene Expression Omnibus (GEO) at http://www.ncbi.nlm.nih.gov/geo/. Expression
profiling data is available at GSE11904 (UPenn) and GSE11985 (UNC) and SNP based copy
number at GSE13282.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Categorization of ccRCCs by HIF-α expression and VHL status
A. Representative HIF-1α and HIF-2α staining of fresh frozen tumors categorized as VHL WT,
H1H2 and H2. Scale bar is 1 μM. B. Summary of VHL disruption in H1H2 and H2 tumors.
Mutations are separated into those occuring in the first two exons or the last. C. Summary of
clinical parameters for each tumor group. In addition to summarized patient characteristics,
histological grade by Fuhrman score and clinical stage by the American Joint Committee on
Cancer Tumor Node Metastasis (TNM) system are shown. Tumors scored as T1 or T2
(confined to the kidney) were considered low stage, while T3, T4, and M1 (invasive or
metastatic tumors) were considered advanced.
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Figure 2. Upregulation of c-Myc cell cycle targets and proliferation in H2 tumors
A. Expression of c-Myc and c-Myc activated targets measured by QRT-PCR. Cyclin D2, E2F1
and c-Myc in VHL WT (n=5), H1H2 (n=8) and H2 (n=8) tumors. Data are shown as a fold
change relative to pooled normal renal epithelium, ±1 SEM. * p<.05, **p<.01. c-Myc
expression was tested with two independent primer sets, as it showed a trend towards
upregulation (FDR =.2) in VHL-deficient vs. VHL WT tumors by microarray analysis. c-Myc
expression was highly variable within tumor groups, and not found significant by QRT-PCR
(p>.25). B. Expression of c-Myc repressed targets p21 and p27, shown as in part A. C.
Representative Ki-67 staining in fresh frozen tumors, with positive nuclei indicated with red
arrows. Scale bar is 0.5 μM. D. Summary of Ki-67 staining from Stage 1,2 (n= 4 VHL WT, 9
H1H2 and 8 H2) Stage 3,4 (n= 2 VHL WT, 3 H1H2 and 3 H2) or both combined. Data are
shown as mean percentage Ki-67 positive ±1 SEM. *p<.05, **p<.01. E. Expression of c-Myc
activated targets and G1-S transition mediators Skp2, CDC7, CDT2 and DHFR, analyzed as
above.
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Figure 3. Microarray analysis defines separable phenotypes in VHL WT, H1H2 and H2 tumors
A. Genes associated with growth factor signaling and protein translation significantly
upregulated in VHL WT and H1H2 tumors relative to H2 tumors. Statistical significance was
measured by false discovery rate (FDR), and fold differences relative to H2 are shown. Gene
names shown in bold have been confirmed by QRT-PCR in VHL WT (n=5), H1H2 (n=8) and
H2 (n=8) tumors. Results for eIF3, and ribosomal protein S, L and P subunits are the average
of genes shown. B. Representative IHC on fresh frozen VHL WT, H1H2 and H2 tumors for
phospho-ERK and phospho-S6. Scale bar is 5 μM. C. Summary of phospho-ERK and phospho-
S6 levels in VHL WT, H1H2 and H2 tumors, scored as weak, intermediate or strong based on
intensity of staining. n=5, 12, and 11 respectively, p<.05. D. Two-way complete linkage
clustering of significantly altered genes between each subgroup identifies both tumors and
genes that show similar patterns of expression. Tumors are identified by color, with VHL WT
highlighted in green, H1H2 in blue, and H2 in red. Red indicates higher levels of expression.
The gene set involved in cell cycle and DNA damage responses are highlighted as this group
was selected for further study.
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Figure 4. H2 tumors exhibit decreased accumulation of γH2AX and genomic aberrancy
A. Enhanced expression of genes associated with HR and the spindle assembly checkpoint in
H2 tumors. Data from VHL WT (n=5), H1H2 (n=8) and H2 (n=8) tumors are shown as a fold
change relative to pooled normal renal epithelium, ±1 SEM. * p<.05, **p<.01. B.
Representative γH2AX/Ki-67 co-staining in fresh frozen VHL WT, H1H2 and H2 only tumors.
DAPI was used to identify nuclei; scale bar is 0.2 μM. C. Quantification of γH2AX staining
in all cells or Ki-67+ cells from VHL WT, H1H2 and H2 tumors (n= 6, 12, and 11 respectively),
±1 SEM. * p<.05, **p<.01. Significant differences also were observed for H1H2 and H2
between all nuclei and Ki-67+ nuclei (p<0.05). D. Characteristic phospho-Chk2/γH2AX co-
staining in a VHL WT, H1H2 and H2 tumor; scale bar is 0.2 μM. E. Measurement of copy
number by Illumina SNP arrays in H1H2 and H2 tumors shows a significantly lower percentage
of the genome is aberrant in H2 tumors (p<.04).
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Figure 5. H2 tumors show enhanced signs of HR-mediated repair
A. Representative BARD1 staining with DAPI to indicate nuclei in VHL WT, H1H2 and H2
tumors. Scale bar is 0.1 μM B. Quantification of BARD1 nuclear staining in 4, 11, and 12
VHL WT, H1H2 and H2 tumors. Weak staining was scored as 0–15, intermediate as 15–30
and strong as >30 foci/nucleus. C. Representative BRCA1/γH2AX co-staining in VHL WT,
H1H2 and H2 tumors; scale bar is 0.1 μM. D. Quantification of BRCA1 foci in γH2AX+ nuclei
from VHL WT, H1H2 and H2 tumors, ±1 SEM. * p<.05, **p<.01.
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Figure 6. HIF-2α/c-Myc effects drive enhanced HR effector expression
A. HIF-1α and HIF-2α expression in control and knockdown cell lines. “H1KD.1” and “H1KD.
2” exhibit HIF-1α knockdown and “H2KD.1” and “H2KD.2” exhibit HIF-2α knockdown.
Actin is shown as a loading control. See Supplemental Fig. 1A for changes in HIF-1α and
HIF-2α mRNA levels in control and knockdown cells. B. Differential expression of c-Myc
activated (Cyclin D2, E2F1) and repressed (p21, p27) targets in control and knockdown cell
lines. Averages are shown from 4 experiments ±1 SEM. C. Expression of G1-S phase cell cycle
targets and HR genes in knockdown cell lines, analyzed as in part B. D. Western blot analysis
of BRCA1 and BARD1 in control and knockdown cell lines; actin is shown as a loading control.
E. QRT-PCR for expression of c-Myc, BRCA1 and BARD1 in control and HIF-1α knockdown
RCC4 clones transfected with control siRNA or two different siRNAs against c-Myc. Average
values from 3 experiments, ±1 SEM. F. Representative images of BRCA1/γH2AX co-staining
in control and HIF-α knockdown cell lines after 3 hr. treatment with 1.5 mM HU. Results from
one control line are shown as both were equivalent results. Scale bar is 0.2 mM.
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Figure 7. HIF-2α/c-Myc effects correlate with resistance to replication stress
A. Western blot analysis of Chk1, Chk2 and γH2AX phosphorylation following 1.5 mM HU
treatment of control and HIF-α knockdown cell lines synchronized in S-phase by timed release
from serum withdrawal and confluency. Total Chk1, Chk2, H2AX and actin are shown as
controls. B. Return to DNA replication following 1 hr. treatment of S-phase synchronized cells
with 1.5 mM HU, measured by BRDU incorporation. Average percent BRDU+ are shown from
3 experiments ±1 SEM. Statistically significant differences between Ctl1 and H1.1, Ctl2 and
H2.2, and H1.1and H2.2 were assessed, * p <.05. C. BRDU incorporation in cells grown for
20 hr. in the presence of 1 μg/ml Aphidicolin. Percentage of cells >2N DNA content is shown,
as is the 2N/BRDU+ percentage. Data from one representative experiment, ±1 SD, * p<.05,
**p<.01. D. Simplified model outlining responses to replication stress. Various stress inducers
have been shown to activate ATR leading to Chk1 phosphorylation and DNA repair, with
replication fork collapse activating ATM, enhancing γH2AX accumulation and promoting cell
cycle exit. These data are consistent with a model where HIF-2α promotes the former pathway
(highlighted in red) and HIF-1α expressing cells tend to exhibit the latter (highlighted in blue).
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Figure 8. TMA analysis of biological parameters and patient outcome
A. Representative HIF-1α and HIF-2α staining from paraffin-embedded TMA cores. Scale bar
is 2 μM B. Summary of patient information and clinical outcomes across IHC determined
groups. Volume was measured in CM3, * p<.05, **p<.01. C. Summary of Ki-67 staining from
low and high stage tumors, or both combined. Data are shown as mean percentage Ki-67
positive ±1 SEM. * p<.05, **p<.01. D. Representative phospho-S6 staining. VHL WT and
H1H2 sections shown were scored as intermediate, and the H2 section as negative, though
endothelial cell phospho-S6 can be noted (red arrows). Scale bar is 0.5 μM E. Summary of
phospho-S6 staining in VHL WT, H1H2 and H2 tumors, * p<.05, **p<.01. F. Representative
γH2AX shown with DAB and fluorescent staining. Middle row also shows DAPI, so that
negative nuclei can be appreciated, whereas lower row shows only γH2AX. Scale bars are 2,
0.5 and 0.2 mM G. Quantification of fluorescent γH2AX staining in all tumors, ±1 SEM. * p<.
05, **p<.01.
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